Compare · CSTL vs HUM
CSTL vs HUM
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $48.02B, about 65.5x CSTL ($732.8M).
- CSTL has been more active in the news (9 items in the past 4 weeks vs 6 for HUM).
- HUM has more recent analyst coverage (25 ratings vs 6 for CSTL).
- Company
- Castle Biosciences Inc.
- Humana Inc.
- Price
- $24.13-0.39%
- $400.21+3.63%
- Market cap
- $732.8M
- $48.02B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 9
- 6
- Recent ratings
- 6
- 25
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest CSTL
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 550 shares at a strike of $2.39 and sold $95,622 worth of shares (4,172 units at $22.92) as part of a pre-agreed trading plan (SEC Form 4)
- Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
- Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
- Chief Operating Officer Oelschlager Kristen M sold $209,650 worth of shares (8,586 units at $24.42) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 21,874 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J sold $238,916 worth of shares (9,836 units at $24.29) as part of a pre-agreed trading plan and exercised 6,214 shares at a strike of $2.39 (SEC Form 4)
- SEC Form 144 filed by Castle Biosciences Inc.
- DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
- Roth Capital initiated coverage on Castle Biosciences with a new price target
- Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
- Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest HUM
- Humana upgraded by Wells Fargo with a new price target
- SEC Form 4 filed by Director Hilzinger Kurt J
- The Humana Foundation Deepens Investment in Emotional Health, Announcing Over $12 Million in New Grants
- SEC Form 11-K filed by Humana Inc.
- SEC Form 11-K filed by Humana Inc.
- Humana Inc. to Release Second Quarter 2026 Results on July 29, 2026
- Humana Awarded Statewide Illinois HealthChoice Medicaid Contract, Expanding Access to Care Across the State
- Humana Announces Agreement to Divest Minority Interest in Gentiva
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach